Sign in
CompletedNo phase

Effects of Photobiomodulation on Insomnia in the Elderly: Clinical Trials of Phototherapy Devices

Key facts

Who runs it
China Medical University Hospital
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
60 people enrolled
Started
26 Apr 2024
Ended
3 Oct 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Bright light
  • Near-infrared light
  • Bright light+ near-infrared light
Record updated
2 December 2025

Who can take part

Age
60 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Pittsburgh Sleep Quality Index score is 8 or above
  • Early wakening ( 30 minutes before expected), or interruptted sleep for more than 30 minutes, lasting for more than 3 months

Who cannot take part

  • Currently taking sedative-hypnotic drugs or receiving other non-drug treatments
  • Movement disorder, inability to move independently
  • Skin diseases, skin cancer, photosensitive skin diseases, or taking drugs that may cause photosensitivity (lithium salts, melatonin, antibiotics, A acid)
  • Eye diseases such as glaucoma, diabetic retinopathy, and cataracts
  • Bipolar disorder
  • Light-induced epilepsy
  • Sleep disorders such as sleep apnea and involuntary leg twitching
  • Those who use cardiac rhythm regulators or artificial cardiopulmonary pacemakers
  • Acute illness
  • Infectious diseases
  • Coagulation disorder
  • Beck depression inventory-II score is greater than 13 points
  • Abnormal blood pressure or fever
  • Pregnancy and pregnant women
  • Special physical abnormalities and sensory nerve abnormalities

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study will recruit 60 participants aged 60 and above, who suffered from insomnia for at least 3 months. Sleep parameters and chronotypes assessed with questionnaires and actigraphy, daytime sleepiness, and biological rhythm (dim light melatonin onset) will be measured. The intervention involves light exposure using a prototype device developed by GCSOL Tech Co., Ltd., a company with expertise in light therapy research and development. Three conditions will be tested (1) bright light; (2) near-infrared light; (3) bright light+ near-infrared light. Data analysis will employ paired t-tests to compare sleep parameters and dim light melatonin onset before and after treatment. Kruskal-Wallis tests and multivariate linear regression will be used to examine differences between intervention groups, controlling for gender and age. Safety analysis will include monitoring adverse events.

The 3 groups in the trial

  • Bright lightExisting treatment, for comparison
  • Near-infrared lightExisting treatment, for comparison
  • Bright light+ near-infrared lightExisting treatment, for comparison

Results explained

A paper that names this trial, explained in plain words.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
2 December 2025